AMSC closed the week at $47.50, up 13% over five days — yet on Tuesday alone it gave back more than 4%. That divergence between a strong weekly move and a sharp single-session reversal captures the tension around American Superconductor right now: options traders are overwhelmingly bullish, but short sellers have been quietly and persistently building positions all month.
The most striking shift in the positioning data is on the short side. Short interest has climbed 26% in a week to 8.4% of the free float — moving from roughly 3 million shares to 3.8 million in just five sessions. The build has been steady since late March, when SI sat closer to 2.6% of float. That is a near-doubling in five weeks. The ORTEX short score has followed, rising from the mid-40s to 51.7 by April 28, edging above the neutral midpoint for the first time in this run. Borrow, however, remains almost frictionless. Cost to borrow sits at just 0.43% — a level that has barely moved all month — and availability in the lending pool is still wide, meaning new short positions are not facing any supply constraint. Shorts are adding conviction, but this is not yet a crowded, expensive trade.
Options tell the opposite story. The put/call ratio has collapsed to 0.22 — the lowest reading of the past year and nearly 1.8 standard deviations below its 20-day average of 0.42. A month ago the PCR was above 0.52. That is an extraordinary swing toward calls. Traders buying upside exposure at the 52-week extreme for bullish options positioning are effectively betting the recent price surge has further to run. The two signals — call-heavy options alongside rapidly growing short interest — are pulling in opposite directions, and the weekly chart of the PCR makes the shift look almost vertical.
The Street is firmly in the bull camp, though analyst data has not been refreshed recently. Consensus from Clear Street and Oppenheimer sits at Buy/Outperform, with a mean price target around $52 — about 10% above the current price. That target was set before the stock's 41% gain over the past month, so the discount to target has compressed sharply, and the upside case may look narrower than the headline figure suggests. On valuation, the PE has expanded to approximately 41x and the EV/EBITDA has pulled back roughly 36 turns over the past 30 days as earnings estimates presumably absorbed the re-rating. The EPS surprise factor score ranks in the 99th percentile — AMSC has been a consistent beater, which partly explains why bulls have tolerated a premium multiple.
Institutional flows offer some context on who has been accumulating. Vanguard added 576,831 shares in the most recent reported quarter, making it the most active buyer among the top holders. Emerald Advisers built a position of nearly 1.2 million shares, adding 364,000 in the latest period. Atreides Management also added 273,000 shares. On the other side, the most recent insider data is from February — a director sold 200 shares, essentially a non-event. The more notable insider history dates to August 2025, when the CEO and CFO sold a combined $8 million-plus of stock at prices in the $54-$55 range. The stock is currently below those levels, which means insiders who sold then timed it well.
Earnings are next on June 3. The last print in February produced a sharp intraday drop of 13.5% before a full five-day recovery of 14.2% — a pattern of initial punishment followed by a rebound. With RSI14 at 68.5 and a month-long rally of 41% into the print, the degree to which the recovery pattern repeats will depend heavily on whether guidance matches the re-rating the market has already priced in. Close peers ENVX and NNE both fell on the day — down 2.2% and 8.0% respectively — suggesting the broader peer group did not help AMSC this week. The June 3 print is therefore less about whether AMSC can beat the quarter and more about whether management's forward commentary justifies a stock that has already run 41% in a month.
See the live data behind this article on ORTEX.
Open AMSC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
